We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more
Bac8.5
Bacopa Monnieri Research
Mostly mechanism / observationalHigh safety
37 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Bacopa Monnieri studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2001–2026 with a typical study size of 62 participants.
Based on 37 studies · 1 meta-analysis · 14 RCTs · 3,834 total participants
Confidence
High
What the studies found
1helped· 36 more without graded effect data
By outcome
Cognitive functionEnhanced memory formation and recall · 8-12 weeks
Mostly mechanism / observational32 studies
Neuroprotection & brain agingBDNF and CNS antioxidant; protects neurons during aging · 8-12 weeks
Depression & moodModerate anxiolytic and mood-stabilizing effects · 8-12 weeks
Mostly mechanism / observational4 studies
Safety profile
Mostly mechanism / observational3 studies
Sleep & insomnia
Too few graded studies2 studies
Energy & fatigue
Too few graded studies2 studies
Glucose & metabolic
Too few graded studies1 study
By the numbers
Pulled from 29 studies with measurable effects
People studied
3,834
typical study: 62 people
Strongest designs
15
1 pooled, 14 randomised
Showed benefit
100%
1/1 studies
How long studies ran
1–4 weeks
1
1–3 months
4
Populations Studied
General population4
Human subjects2
Healthy adults2
Schizophrenia patients1
Active research area
23 studies in the last 5 years · Latest meta-analysis: 2014
200120132026
1Schizophrenia symptom managementSystematic ReviewCited 2×n=103 · medium study2025
It is recommended that additional research elucidating the effects of Brahmi in other models of schizophrenia and the possible mechanisms of action be conducted.
Ayilara GO et al. · Nutritional neuroscience (2025)
Schizophrenia is a psychotic disorder affecting approximately 0.32% of the global population.
Data analysis was done by using themes.
The review found that Brahmi could reverse positive, negative, and cognitive symptoms of schizophrenia.
2Herbal medicine use patterns for epilepsy seizuresSystematic ReviewCited 38×n=2,017 · very large study2019
Species with the highest use report were not those with pharmacological evaluation.
Auditeau E et al. · Journal of ethnopharmacology (2019)
Species with the highest use report were not those with pharmacological evaluation.
It will be pertinent to assess the pharmacological effects and safety of medicinal plants used mostly by traditional healers on predictive models of seizures.
5Prostate cancer managementSystematic ReviewCited 3×2025
Despite strong evidence of efficacy of these plants to potentially improve the outcome of prostate cancer, clinical trials are required to evaluate which plants may be most efficacious and to determine effective dosing strategies, as well as the use of ayurvedic plants as standalone therapies or in combination with conventional prostate cancer treatments.
Jabbari P et al. · Integrative cancer therapies (2025)
As such, there is an urgent need for novel therapeutic options in treating this malignancy.
This review examines the pre-clinical evidence for Ayurveda medicinal plants such as Withania somnifera, Glycyrrhiza spp, Momordica spp, Boswellia, and Bacopa monnieri and their potential application in managing prostate cancer.
Several in-vitro and pre-clinical studies suggest potentials for these plants or their derivatives in preventing or treating prostate cancers.
6Type 2 diabetes mellitus and neurodegeneration managementSystematic ReviewCited 1×2025
Network pharmacology and protein-protein interaction analyses confirm bacoside-A's regulatory roles in NOTCH signalling, insulin receptor expression, and hepatic enzyme modulation.
Dadhich A et al. · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2025)
Network pharmacology and protein-protein interaction analyses confirm bacoside-A's regulatory roles in NOTCH signalling, insulin receptor expression, and hepatic enzyme modulation.
Collectively, these findings validate BM as a viable, low-toxicity candidate for next-generation phytopharmaceutical development in the holistic management of diabetes and its complications.
7Cognitive function and nootropic effectsSystematic ReviewCited 31×2023
Together, the results from the compiled studies highlight the nootropic effects and the inconsistencies regarding PDNs that require further research.Supplemental data for this article is available online at https://doi.org/10.1080/10408398.2021.2021137.
Lorca C et al. · Critical reviews in food science and nutrition (2023)
Bacopa monnieri improves language, learning and memory.
Withania somnifera (Ashwagandha) modulates anxiety and social-related cognitions.
Caffeine enhances attention and executive functions.
Srivastava P et al. · Current pharmaceutical design (2024)
Here, we focused on neurological problems as we examined the pharmacological and phytochemical characteristics of BME.
For their effective usage in neuroprotection and cognition, many clinical concerns and the synergistic potential of Bacopa extract have been investigated.
Alzheimer's disease is a neurological condition caused by the production of reactive oxygen species, which also causes amyloid-beta (Aβ) and tau protein aggregation and increases neuro-inflammation and neurotoxicity.
Vinod A et al. · Current topics in medicinal chemistry (2022)
The active constituents and metabolites responsible for the effects of BM could be bacoside A and B, bacopaside I and II, bacopasaponin C, betulinic acid, asiatic acid, loliolide, ebelin lactone, and quercetin.
We have also discussed CDRI-08, clinical trials, safety, emerging formulation technologies, as well as BM combinations, and dietary supplements.
The present review is a comprehensive and up-to-date analysis supported by the evidentiary proofs from pre-clinical studies, meta-analyses, and review papers related to natural phytochemicals' impact on neurodegenerative disorders like AD.
Khandia R et al. · Current Alzheimer research (2022)
The present review is a comprehensive and up-to-date analysis supported by the evidentiary proofs from pre-clinical studies, meta-analyses, and review papers related to natural phytochemicals' impact on neurodegenerative disorders like AD.
Luthra R et al. · Current pharmaceutical biotechnology (2022)
Variation in transcription and transduction pathways plays a vital role in the preventive measures of plants in such diseases.
Neurodegenerative diseases are generally caused by the depletion of proteins, oxidative and inflammatory stress, environmental changes and so on, with aging being the most important cause.
Natural compounds can be used in order to treat neurodegenerative diseases Medicinal plants such as Ginseng, Withania somnifera, Bacopa monnieri, Ginkgo biloba, etc. are some of the medicinal plants for the prevention of neurological symptoms.
Potential solutions to address research gaps are offered, for future research next steps, which is needed to strengthen the evidence and inform decisions.
Crawford C et al. · Journal of alternative and complementary medicine (New York, N.Y.) (2021)
Ingredients evaluated included Bacopa monnieri, choline, creatine, omega-3 fatty acids, Ginkgo biloba, ginseng, Rhodiola rosea, tyrosine, and valerian root, all in supplement form and compared with a placebo, at various serving sizes and durations of use.
Whereas certain trends regarding promising serving sizes or duration for use, are pointed to in this synthesis, when combined, studies are inconsistent and imprecise, and many are methodologically flawed.
Potential solutions to address research gaps are offered, for future research next steps, which is needed to strengthen the evidence and inform decisions.
The review demonstrates the neuroprotective potential of the Ayurveda herb Brahmi in several disorders including Alzheimer's disease, epilepsy, Parkinson's disease, Huntington's disease, cerebral ischemia and infarct and neoplasms.
Shalini VT et al. · Molecular biology reports (2021)
Numerous research have been undertaken across the globe to evaluate the neuroprotective potential of this herb.
This review collates and summarises current (as on May 2020) published literature on Brahmi as a neuroprotective in neurological and psychiatric disorders.
English language articles from databases PubMed, Scopus and Google scholar were searched using appropriate free keywords and MeSH terms related to the topic.
This comprehensive review covers literature up to the year 2020 highlighting all the anticancer efficacy along with signaling pathways activated by secondary metabolites found in bacopa plant.
Ghosh S et al. · Nutrition and cancer (2021)
In recent years, research on the biological effects of Bacopa monnieri has flourished as promising neuroprotective, memory boosting and more importantly as both chemopreventive and anti-neoplastic agent.
Each naturally synthesized chemical constituent identified from Bacopa monnieri leaf extract with different solvents, has significant anti-metastatic, anti-angiogenic and anti-proliferative activity on different type of cancer cells.
In this context, a substantial literature survey allows a deep understanding of the involvement of specific bioactive molecules along with the whole plant extract of Bacopa monnieri with their divergent effective molecular pathways.
Overall, nearly one-quarter (23%) of adults currently take a supplement to maintain or improve brain health or delay and reverse dementia.
However, other botanicals that affect stress, focus, attention, and sleep have also been procured by dietary supplement companies developing products for improving both, short and long-term brain health.
Botanicals are discussed in terms of available clinical efficacy data and current safety profiles.
18Systematic ReviewCited 7×n=14 · very small study2023
Overall, this review found that there is a low quality of evidence regarding the efficacy of cognitive function and safety of herbal and nutritional medicines for older adults with and without SCI, due to a high risk of bias across studies.
Cave AE et al. · Systematic reviews (2023)
Overall, this review found that there is a low quality of evidence regarding the efficacy of cognitive function and safety of herbal and nutritional medicines for older adults with and without SCI, due to a high risk of bias across studies.
Additionally, further work needs to be done in classifying and understanding SCI and selecting appropriate trial primary outcomes before future studies can more accurately determine the efficacy of interventions for this population.
19BDNF modulation by botanicalsSystematic ReviewCited 36×2017
Further clinical studies are mandatory to confirm botanicals as preventive agents or as useful adjuvant to the pharmacological treatment.
Sangiovanni E et al. · Neural plasticity (2017)
The effect of the active principles responsible for the efficacy of the extracts is reviewed and discussed as well.
The high number of articles published (more than one hundred manuscripts for 14 botanicals) supports the growing interest in the use of natural products as BDNF modulators.
The studies reported strengthen the hypothesis that botanicals may be considered useful modulators of BDNF in CNS diseases, without high side effects.